COLO-B

Coloplast A/S occupies a rare position in European healthcare: a company whose products are deeply intimate, clinically habitual, and structurally resistant to disruption, yet whose stock has lost more than 40 percent of its value from its 52-week high near DKK 748 to a recent price around DKK 425. That gap between structural resilience and market repricing is the central analytical question. The share price decline is not a story of franchise erosion. It is a story of margin dilution, integration costs, and a market recalibrating its willingness to pay a premium multiple for a company temporarily burdened by the financial aftershocks of its largest acquisition in history.

The company reported FY2025 revenue of DKK 27.9 billion, up from DKK 27.0 billion the prior year, continuing a five-year trajectory that has seen top-line growth from DKK 19.4 billion in FY2021. Revenue has compounded at roughly 7.5 percent annually over that period. Yet net income fell to DKK 3.6 billion in FY2025 from DKK 5.1 billion in FY2024, a decline of nearly 28 percent. Diluted EPS dropped from DKK 22.46 to DKK 16.13. For four consecutive quarters in FY2025, Coloplast missed analyst EPS estimates by margins ranging from 17 to 27 percent. The market does not punish persistent EPS misses of that magnitude without consequence, and the share price reflects that punishment.

The central L17X insight is this: Coloplast is not a company whose moat is weakening. It is a company whose moat is being obscured by the financial complexity of absorbing Atos Medical, the voice and respiratory care specialist acquired in stages during FY2022 and FY2023. The DKK 29.8 billion in goodwill and intangible assets sitting on the balance sheet, representing over 61 percent of total assets, is the accounting manifestation of this strategic bet. The question is not whether Coloplast's chronic care franchise retains its structural power. It does. The question is how long the integration costs, elevated interest expense (DKK 825 million in FY2025, up from DKK 57 million in FY2021), and tax burden adjustments (effective tax rate reaching 41 percent in FY2025) will compress returns before the underlying earnings power reasserts itself. This is a company where the moat is intact but the income statement is temporarily impaired, and the analytical challenge lies in distinguishing structural deterioration from cyclical absorption.